Introduction p53-upregulated modulator of apoptosis (PUMA), a BH3-only Bcl-2 family member, plays an essential role in apoptosis induced by a variety of stimuli. In response to DNA-damaging agents, such as chemotherapeutic drugs and ionizing radiation, p53 tumor suppressor activates the transcription of PUMA to induce apoptosis (Nakano and Vousden, 2001; Yu et al., 2001) . Other apoptotic stimuli can activate PUMA independent of p53 (Han et al., 2001) . Deletion of PUMA in human cancer cells abrogates apoptosis induced by p53, DNAdamaging agents, hypoxia, endoplasmic reticulum (ER) stress and HIV proteins (Reimertz et al., 2003; Perfettini et al., 2004) . In mice, PUMA is required for p53-dependent apoptosis induced by g-irradiation, DNA-damaging drugs, c-Myc and E1A oncogenes, as well as p53-independent apoptosis induced by cytokine withdrawal, glucocorticoids, kinase inhibitors and phorbol esters (Jeffers et al., 2003; Villunger et al., 2003) . Deficiency in PUMA promotes oncogenic transformation and accelerates lymphomagenesis induced by the em-myc oncogene, suggesting a role of PUMA in tumor suppression (Hemann et al., 2004) .
PUMA is localized in the mitochondria and regulates apoptosis through other members of the Bcl-2 family. PUMA interacts with antiapoptotic proteins Bcl-2 and Bcl-X L , and is dependent on Bax to induce apoptosis (Yu et al., 2001 . In response to PUMA expression, Bax translocates from the cytosol into the mitochondria and forms multimers in the mitochondria . PUMA also promotes collapse of mitochondrial membrane potential . However, it remains unclear how these mitochondriarelated events are coordinated to initiate PUMAinduced apoptosis.
During apoptosis execution in mammalian cells, several apoptogenic proteins are released from the mitochondria into the cytosol to trigger downstream apoptotic events (Green and Reed, 1998; Wang, 2001; Cory et al., 2003; Danial and Korsmeyer, 2004) . For example, cytochrome c is released to form, along with Apaf-1 and caspase-9, an 'apoptosome' and initiates caspase activation cascade (Wang, 2001 ). Release of apoptosis-inducing factor (AIF) leads to chromatin condensation and nuclear fragmentation (Susin et al., 1999) . Second mitochondria-derived activator of caspase (SMAC), also called direct inhibitor of apoptosis proteins (IAP)-binding protein with low pI (Diablo), was also found to be released into the cytosol of apoptotic cells (Du et al., 2000; Verhagen et al., 2000) . SMAC/Diablo (hereafter referred to as SMAC) interacts with and antagonizes IAPs, such as XIAP, cIAP1 and cIAP2 (Verhagen et al., 2000) . SMAC expression and agents that mimic the IAP interacting function of SMAC sensitize human cancer cells to apoptosis induced by several anticancer agents, such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) (Fulda et al., 2002; Arnt and Kaufmann, 2003; Li et al., 2004) . Although substantial evidence suggests that SMAC plays an important role in execution of apoptosis, the precise function of SMAC remains obscure. In SMAC-deficient mice, cell death induced by a variety of stimuli was not found to be altered (Okada et al., 2002) . Furthermore, the mechanisms by which SMAC and other mitochondrial apoptogenic proteins are released into the cytosol during execution of apoptosis are poorly understood.
Our previous study in colon cancer cells demonstrated the involvement of SMAC in apoptosis induced by nonsteroidal anti-inflammatory drugs (NSAIDs) (Kohli et al., 2004) . Studies by other groups suggest the existence of a caspase-mediated feedback amplification loop in regulating cytochrome c release and other mitochondrial events in apoptosis (Chen et al., 2000; Lakhani et al., 2006) . These studies prompted us to investigate the role of SMAC in PUMA-induced apoptosis, as well as its potential involvement in PUMA-induced mitochondrial events during execution of apoptosis.
Results

PUMA induces cytochrome c, SMAC and AIF release in colon cancer cells
Our previous studies demonstrated that PUMA-induced apoptosis in HCT116 colon cancer cells is dependent on Bax and occurs through a mitochondrial pathway (Yu et al., 2001 . To study Bax-mediated downstream events, we infected parental HCT116 cells and BAXknockout (BAX-KO) cells with an adenovirus expressing PUMA (Ad-PUMA), and analysed the cytosolic release of cytochrome c, SMAC and AIF. All three proteins were found to be enriched in the cytosol of HCT116 cells undergoing PUMA-induced apoptosis, but not present in the cytosol of BAX-KO cells resistant to apoptosis (Figure 1a) . The Bax-dependent release of cytochrome c, SMAC and AIF was not unique for Ad-PUMA treatment, and also observed in cells undergoing apoptosis induced by the DNA-damaging agent etoposide ( Figure 1b) .
We then examined whether apoptosis mediated by endogenous PUMA also involves the release of mitochondrial apoptogenic proteins. Our previous study showed that Adriamycin, a DNA-damaging agent commonly used in chemotherapy, could induce apoptosis in HCT116 cells in the absence of the cyclindependent kinase (CDK) inhibitor p21, and such apoptosis is strictly PUMA-dependent . Our recent study showed that PUMA is responsible for Adriamycin-induced Bax activation and subsequent mitochondrial changes (Ming et al., 2006) . Therefore, p21-knockout (p21-KO) and p21/ PUMA double knockout (p21-KO/PUMA-KO) HCT116 cells were compared following Adriamycin treatment. We found that in the p21-KO cells, but not in the p21-KO/PUMA-KO cells, Adriamycin could induce the release of cytochrome c, SMAC and AIF (Figure 1c) , as well as mitochondrial membrane permeabilization (Figure 1d ), suggesting that Baxdependent release of cytochrome c, SMAC and AIF plays an important role in the execution of PUMAmediated apoptosis.
To further study the role of mitochondrial apoptogenic proteins in PUMA-induced apoptosis, we compared HCT116 and four additional colorectal cancer cell lines. In each case, cytochrome c, SMAC and AIF were found to be released into the cytosol in the cells undergoing apoptosis following Ad-PUMA infection (Figure 1e) . However, the release of SMAC appeared to be more significant compared with that of cytochrome c or AIF, with over 90% of mitochondrial SMAC released 48 h after Ad-PUMA infection in each of the five cell lines (Figure 1e) . Interestingly, the amount of cytosolic SMAC seemed to correlate best with the extent of apoptosis in these cells (Figure 1e ). These results suggest a consistent involvement of mitochondrial apoptogenic proteins and a prominent role of SMAC in execution of PUMA-mediated apoptosis in colon cancer cells.
PUMA-induced apoptosis is inhibited in SMAC-deficient cells, but not in AIF-deficient cells To determine whether SMAC release is relevant, or just a coincidental event in PUMA-induced apoptosis, we analysed SMAC-knockout (SMAC-KO) HCT116 cells that we previously created by homologous recombination (Kohli et al., 2004) . After Ad-PUMA infection, significantly less apoptosis was detected by nuclear staining in the SMAC-KO cells compared with that in the parental cells 48 h after treatment (18 vs 68%; Figure  2a and b). Analysis of apoptosis by different methods, including cell cycle analysis and Annexin V staining, confirmed that PUMA-induced apoptosis is inhibited in the SMAC-KO cells (Figure 2c and d) .
If these observations were indeed due to the deficiency in SMAC, we would expect that PUMA-induced apoptosis can be restored by reconstitution of SMAC expression. Therefore, a SMAC-reconstituted cell line (SMAC-R) we previously generated was analysed for its response to PUMA (Kohli et al., 2004) . PUMA-induced apoptosis was found to be completely restored by the reconstituted SMAC in the SMAC-KO cells . To rule out the possibility that these observations are due to the specific genetic background of HCT116 cells, we analysed SMAC-deficient DLD1 colon cancer cells (SMAC-KD) generated by stable transfection of small interference RNA (siRNA) (Kohli et al., 2004) . Knockdown of SMAC in DLD1 cells led to a significant decrease in PUMA-induced apoptosis, as determined by nuclear staining, Annexin V staining and cell cycle analysis ( Figure 3 and data not shown).
To test if the effect of SMAC on PUMA-induced apoptosis is specific, RNA interference (RNAi) was used to knock down the expression of AIF in HCT116 cells as described in the Materials and methods. Two stable cell lines with markedly decreased expression of AIF were isolated after puromycin selection ( Figure 4a ). Both cell lines were found to be as sensitive as the parental HCT116 cells to PUMA-induced apoptosis (Figure 4b ), suggesting that the role of AIF may not be as important as that of SMAC in execution of PUMA-induced apoptosis.
Caspase activation, cytochrome c release and mitochondrial membrane potential collapse are inhibited in the SMAC-deficient cells It was shown that following its release from the mitochondria into the cytosol, SMAC promotes caspase activation (Du et al., 2000; Verhagen et al., 2000) . We therefore examined whether caspases, including caspases-3 and caspases-9, can still be cleaved in the SMAC-deficient cells. Upon Ad-PUMA infection, The results are the average of three independent experiments with one standard deviation shown. Cox IV and a-tubulin, which are exclusively expressed in the mitochondria and cytosol, respectively, were used as controls for loading and fractionation.
SMAC/Diablo-mediated proapoptotic function of PUMA J Yu et al cleavage of both caspases was found to be significantly decreased in the SMAC-KO and SMAC-KD cells, compared with that in the parental HCT116 and DLD1 cells, respectively (Figure 5a and data not shown). Reconstitution of SMAC expression completely restored caspase activation in the SMAC-KO cells (Figure 5a ). Caspase activation was not detectable in the BAX-KO cells that are deficient in SMAC release and resistant to PUMA-induced apoptosis, suggesting that SMAC regulates a large extent of PUMA-induced and Bax-dependent caspase activation (Figures 1 and  5a) . Activation of caspase-3 and caspase-9 was also decreased in SMAC-KO cells undergoing apoptosis induced by the DNA-damaging agent etoposide (Figure 5b ). In contrast, treating the cells with N-acetylleu-leu-norleucinal (ALLN), a proteasome inhibitor, which does not rely on SMAC to induce apoptosis (Kohli et al., 2004) , led to similar extent of caspase-3 and caspase-9 activation in the parental HCT116 and SMAC-KO cells (Figure 5b) , suggesting that the role of SMAC in apoptosis is limited to certain stimuli.
To understand the mechanisms by which SMAC mediates PUMA-induced caspase activation, we analysed the release of cytochrome c and mitochondrial membrane potential change in the SMAC-KO cells. We found that cytochrome c release was significantly decreased in the SMAC-KO cells compared with that in the parental cells, which correlated with changes in apoptosis and caspase activation (Figure 5c ). Time course experiments revealed that the release of cytochrome c and AIF were both impaired and delayed in the SMAC-KO cells compared with that in the parental (Figure 5d ). Furthermore, mitochondrial membrane permeabilization induced by PUMA is much reduced in the SMAC-deficient cells (Figure 5e ). Mitochondrial membrane potential change was completely restored by reconstitution of SMAC expression (Figure 5e ). These data suggest that SMAC mediates PUMA-induced apoptosis and Caspase activation by promoting mitochondrial membrane potential collapse and cytochrome c release.
SMAC and SMAC mimetics sensitize cells to PUMA-induced apoptosis
The above data suggest that activation of SMAC may enhance PUMA-mediated apoptosis. To test this possibility, we examined whether overexpression of SMAC has an effect on apoptosis induced by Ad-PUMA in HCT116 cells. Cells were transfected with SMAC or the control empty vector before Ad-PUMA infection. Indeed, transfection with SMAC, but not the control empty vector, significantly enhanced PUMAinduced apoptosis in HCT116 cells (Figure 6a ). Our data suggest that SMAC is involved in a feedback amplification loop to promote cytochrome c release and other mitochondrial events in execution of apoptosis. If this is the case, we would expect that the SMAC-mediated IAP inhibition is also involved in PUMA-mediated apoptosis. To test this possibility, we examined whether pharmacological agents that mimic the IAP inhibition function of SMAC have similar effects on PUMA-induced apoptosis. A small molecule mimics the AVPI amino-acid residues of SMAC that are responsible for IAP binding (C3) and a control compound (C4), which differs from C3 by a single methyl group, were used to treat the cells (Li et al., 2004) . It was previously shown that C3, but not C4, at nanomolar concentrations can bind to IAPs and sensitize human cancer cells to TRAIL and TNF-ainduced apoptosis (Li et al., 2004) . When used alone at 100 nM, both compounds have no effect on cell growth and do not induce significant apoptosis (Figure 6b and data not shown). However, 100 nM of C3 significantly enhanced apoptosis induced by Ad-PUMA in HCT116 cells (Figure 6b ). In contrast, PUMA-induced apoptosis was not affected by the control compound C4 (Figure 6b) .
Taken together, our data indicate that SMAC plays an important role in execution of DNA damage-induced and PUMA-mediated apoptosis. Our data also suggest that SMAC does so by participating in a feedback amplification loop to promote cytochrome c release and other mitochondrial events. 
Discussion
Understanding the mechanisms of PUMA-mediated apoptosis has important implications for anticancer therapy. PUMA is a p53 target and an essential mediator of DNA damage-induced apoptosis . Chemotherapy and radiation often cause DNA damage, which induces cell cycle arrest and apoptosis in cancer cells. Deficiencies in apoptosis regulation contribute to acquired resistance to anticancer drugs (Johnstone et al., 2002) . A number of studies have demonstrated that SMAC and SMAC mimetics potentiate apoptosis induced by anticancer agents, including chemotherapeutic drugs and irradiation, in human cancer cells (Fulda et al., 2002; Arnt and Kaufmann, 2003; Giagkousiklidis et al., 2005; Zhao et al., 2006) . Efforts have also been made to develop improved SMAC mimetic agents (Li et al., 2004; Sun et al., 2004) . However, the precise function of SMAC in promoting apoptosis induced by anticancer agents was unclear. Our previous studies demonstrated that in response to DNA damage, PUMA dissociates Bax from the antiapoptotic protein Bcl-X L , leading to Bax mitochondrial translocation and multimerization, which in turn triggers mitochondrial membrane permeabilization and subsequent release of cytochrome c, SMAC and AIF Ming et al., 2006) . The current study suggests that SMAC plays an important role in executing DNA damage-induced and PUMA-mediated apoptosis by participating in a feedback amplification loop and other mitochondrial events, which implies that SMAC enhances the antitumor activities of chemotherapeutic drugs and irradiation by promoting the proapoptotic function of PUMA. Although SMAC release is a general response to different apoptotic stimuli (Deng et al., 2002; Arnt and Kaufmann, 2003; Rashmi et al., 2005) , the requirement of SMAC in apoptosis appears to be somewhat specific. Among a number of stimuli analysed, only a few, including Ad-PUMA, NSAIDs and certain DNA-damaging agents, were found to induce SMAC-dependent apoptosis and caspase activation (Kohli et al., 2004) .
Mitochondrial apoptogenic proteins were initially identified as important regulators of apoptosis by biochemical studies. Recently, studies carried out using genetically engineered animals indicate that these proteins are required for apoptosis under certain conditions. For example, knock-in of a cytochrome c mutant that fails to activate Apaf-1 in mice abrogates caspase activation and apoptosis in fibroblasts (Hao et al., 2005) . Knockout of AIF in mice inhibited neuronal cell death (Yu et al., 2002) . However, targeted deletion of SMAC in mice was not found to influence murine development and apoptosis in several tissues, raising the question whether SMAC is required for apoptosis in mammalian cells (Okada et al., 2002) . Our data suggest that the role of SMAC in apoptosis varies depending on cell types and apoptotic stimuli. In colon cancer cells, SMAC plays an important role in executing apoptosis induced by PUMA and NSAIDs (Kohli et al., 2004) . The partial phenotypes observed in the SMAC-KO cells in both cases, as well as the observation that SMAC deficiency does not rescue cells' long-term viability in clonogenic assays (data not shown), suggest that the function of SMAC in apoptosis is limited to the execution, rather than the commitment stage of apoptosis. As a result, apoptotic cell death cannot be fully executed without SMAC, but cells may eventually die through other mechanisms such as necrosis and autophagy (Okada and Mak, 2004) . However, the function of SMAC in the execution of apoptosis warrants further examination using different experimental systems and additional apoptotic stimuli.
Although the release of mitochondrial apoptogenic proteins is known to be critical for apoptosis execution and caspase activation, the mechanism of this process is poorly understood. Our data obtained from two different models, that is, PUMA-and NSAID-induced apoptosis, suggest that the release of SMAC and that of cytochrome c or AIF may play a different role in apoptosis. These events also seem to be related to each other. It appears that SMAC itself is involved in promoting mitochondrial membrane potential change, thereby mediating cytochrome c release and caspase activation. These results are consistent with a recent study showing that the release of different mitochondrial , 2006) . It has been shown that caspase activation can occur before mitochondrial permeabilization (Lassus et al., 2002) . A feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress-induced apoptosis has been proposed (Chen et al., 2000) . Recent studies also suggest that caspase-3 and caspase-7 are involved in a feedback amplification loop in triggering cytochrome c release and other mitochondrial events in apoptosis (Lakhani et al., 2006) . It is possible that SMAC participates in this feedback SMAC/Diablo-mediated proapoptotic function of PUMA J Yu et al amplification loop by providing the initial caspase activity to unleash further mitochondrial changes that are necessary for full execution of apoptotic events. However, other mechanisms have also been proposed to explain how SMAC and cytochrome c can affect each other during apoptosis initiation. A recent study showed that SMAC release is suppressed in cytochrome cdeficient cells (Hansen et al., 2006) . It has been shown that SMAC and cytochrome c are released together from the mitochondria during UV-induced apoptosis (Zhou et al., 2005) . Therefore, questions remain as to how SMAC release affects other mitochondria-related events during apoptosis, and whether its function in regulating mitochondrial events is related to IAP inhibition.
Materials and methods
Western blotting
The antibodies used for Western blotting included those against caspase-9 (Cell Signaling Technology, Danvers, MA, USA), cytochrome c, a-tubulin (BD Biosciences, San Jose, CA, USA), caspase-3 (Assay Designs & Stressgen Bioreagents, Ann Arbor, MI, USA), cytochrome oxidase subunit IV (Cox IV) (Invitrogen, Carlsbad, CA, USA), Bax (N-20), AIF (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and SMAC (a generous gift from Dr Eileen White at Rutgers University, Piscataway, NJ, USA). Western blotting analysis was performed as previously described (Kohli et al., 2004) .
Cell culture and transfection
The cell lines used in this study, including HCT116 colorectal cancer cell derivatives SMAC-knockout (SMAC-KO), SMAC-KO reconstituted with SMAC (SMAC-R), BAX-knockout (BAX-KO), p21-knockout (p21-KO), p21/PUMA double knockout (p21-KO/PUMA-KO) and SMAC-knockdown DLD1 cells (SMAC-KD) were previously described (Waldman et al., 1995; Zhang et al., 2000; Kohli et al., 2004) . All cell lines were cultured in McCoy's 5A media (Invitrogen) supplemented with 10% defined fetal bovine serum (Hyclone, Logan, UT, USA), 100 U/ml penicillin, 100 mg/ml streptomycin (Invitrogen), and were maintained at 371C in 5% CO 2 . Cells were transfected by Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. To induce apoptosis, cells were plated at B20% density and allowed to attach for 12 h. Ad-PUMA and mutant PUMA with a BH3 domain deletion (Ad-DBH3) were used to infect cells . Adriamycin (0.2 mg/ml) was used to treat p21-KO and p21-KO/PUMA-KO cells. Etoposide and ALLN were used at 200 and 50 mM, respectively. The SMAC mimetic and control compounds were provided by Dr Xiaodong Wang and Dr Patrick G Harran at the University of Texas Southwestern Medical Center (Li et al., 2004) .
Apoptosis assays
After treatment, floating and adherent cells were collected and analysed for apoptosis by nuclear staining. Briefly, cells were fixed in 70% ethanol and stained with phosphate-buffered saline solution containing 0.1% Triton X-100, 50 mg/ml RNaseA and 5 mg/ml propidium iodide (PI). Apoptotic cells, which contain condensed chromatin and fragmented nuclei, were counted after microscopic visualization. For each treatment, cells were counted three times and a minimum of 300 cells were analysed. The PI-stained cells were also subjected to flow cytometry to determine the fraction of sub-G 1 population. For analysis of apoptosis by Annexin V staining, cells were stained by Annexin V-Alexa 594 (Molecular Probes) following the manufacturer's instructions, counterstained by 4 0 ,6-diamidino-2-phenylindole, dihydrochloride (DAPI) and then analysed by flow cytometry. For detection of mitochondrial membrane potential change, cells were harvested and stained by Mitotracker Red CMXROS (Molecular Probes) for 15 min at room temperature and then analysed by flow cytometry on a Beckman Coulter (Fullerton, CA, USA) EPICS XL using the FL3 channel according to the manufacturer's instructions.
Analysis of cytochrome c, SMAC and AIF release Mitochondrial and cytosolic fractions were isolated from treated cells by differential centrifugation. Briefly, cells were washed, resuspended in homogenization buffer (0.25 M sucrose, 10 mM HEPES, pH 7.4 and 1 mM ethylene glycol bis(b-aminoethylether)-N,N,N 0 ,N 0 ,-tetraacetic acid) and subjected to 40 strokes of homogenization in a Dounce homogenizer. The homogenates were centrifuged at 1000 g for 15 min at 41C to pellet nuclei and unbroken cells. The supernatant was subsequently centrifuged at 10 000 g for 15 min at 41C to obtain cytosolic fraction (supernatant) and mitochondrial fraction (pellet). The mitochondrial fraction was resuspended in homogenization buffer following one wash. Both fractions were mixed with equal volumes of 2 Â Laemmli sample buffer for Western blotting analysis.
Knockdown of AIF by RNA interference Nucleotides 481-499 (GATCCTGAGCTGCCGTACA) within the AIF coding sequence was selected as the target for RNAi. Two 64-base oligonucleotides containing this sequence were designed based on previously described criteria (Elbashir et al., 2002) . The oligonucleotides were annealed and the duplex was cloned into the pSUPER vector (Oligoengine, Seattle, WA, USA), which can direct the synthesis of siRNA (Brummelkamp et al., 2002) . Forty-eight hours following transfection with the RNAi constructs, HCT116 cells were plated in 96-well plates in the presence of Puromycin (2 mg/ml, Invitrogen). Puromycin-resistant clones were isolated and expanded. Clones with significant downregulation of AIF were identified by Western blotting.
